Low-Dose Naltrexone (LDN) vs Pentosan (Joint Pain)
A side-by-side research comparison of Low-Dose Naltrexone (LDN) and Pentosan (Joint Pain) across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Low-Dose Naltrexone (LDN) | Pentosan (Joint Pain) |
|---|---|---|
| Full name | Low-Dose Naltrexone | Pentosan Polysulfate Sodium (Cartrophen) |
| Category | Pain & Inflammation | Pain & Inflammation |
| Status | Off-label prescription | FDA Approved (interstitial cystitis) / Veterinary approved |
| Mechanism | Brief nocturnal opioid receptor blockade triggers compensatory upregulation of endogenous opioid production and OGF (opioid growth factor), modulating immune cell proliferation and reducing inflammatory cytokines. | Inhibits matrix metalloproteinases (MMPs) and aggrecanases that degrade cartilage. Stimulates hyaluronic acid production by synoviocytes. Promotes proteoglycan synthesis by chondrocytes. Reduces subchondral bone remodeling via anti-inflammatory effects. |
| Molecular weight | 341.40 Da | ~4000-6000 Da (average) |
| Half-life | ~4 hours | ~24 hours |
| Bioavailability | ~5-40% oral (first-pass) | ~6% oral; ~100% subcutaneous |
| Typical dose | 1.5-4.5 mg | 2-3 mg/kg SC (veterinary extrapolation) or 100mg oral 3x/day |
| Frequency | Nightly at bedtime | Weekly SC injections (4-6 course) or daily oral |
| Route | Oral capsule (compounded) | Subcutaneous injection or oral capsule |
Low-Dose Naltrexone (LDN) reported benefits
- Immune modulation
- Reduced inflammation
- Chronic pain relief
- Autoimmune support
- Improved mood via endorphins
- Weight loss support
Pentosan (Joint Pain) reported benefits
- Cartilage protection and repair
- Reduced joint inflammation
- Improved synovial fluid
- Disease-modifying (not just symptomatic)
- Reduced bone marrow edema
- Alternative to corticosteroid injections
Related comparisons
Research and educational reference only. Not medical advice.